Press Releases

Grifols Welcomes S&P Global Ratings’ Upgrade to ‘BB-’ with Stable Outlook December 17 2025

Grifols obtains approval from the European Medicines Agency for the entire value chain of Grifols Egypt December 16 2025

Grifols Secures 95% of Investor Support to Improve Documentation Terms of Its €1.3 Billion 7.5% Secured Notes November 12 2025

Grifols Welcomes Fitch Ratings’ Outlook Revision to Positive and Affirmation of 'B+' Rating November 7 2025

Grifols reports quarterly revenues of EUR 1,865 million and group profit of EUR 127 million November 4 2025

Grifols creates the Board of Directors' Strategy Committee September 29 2025

Grifols Reports 7% Revenue Growth to EUR 3,677m and Net profit to EUR 177m in H1’25 while executes on its Value Creation Plan July 29 2025

Grifols successfully completes Biotest delisting June 11 2025

Anne-Catherine Berner, new Grifols Chair June 5 2025

Moody’s upgrades Grifols corporate family debt rating to B2 with a positive outlook May 22 2025

Grifols delivers strong results across the board, increasing revenues by 7.4%, Adj EBITDA by 14.2% and improving free cash flow by EUR 209m May 12 2025

Grifols expects to reach EUR 10 billion in revenue, EUR 2.9 billion in EBITDA and EUR 3.5+ billion in cumulative cash flow by 2029 February 27 2025

Grifols delivers a strong 2024 exceeding guidance on revenue and free cash flow February 26 2025

Thomas Glanzmann to retire as Grifols Chairman and will be succeeded by Board member Anne-Catherine Berner February 25 2025

Grifols ranked number one biotech company in Dow Jones Sustainability Indices December 16 2024

Grifols concludes balance sheet improvement process with private placement of Senior Secured Notes and Revolving Credit Facility extension December 11 2024

Grifols’ Board of Directors Announces Termination of Acquisition Discussions with Brookfield November 27 2024

Grifols Delivers Strong Third-Quarter Performance Led by Biopharma 12.1% Growth November 7 2024

Grifols awarded Gold Medal by EcoVadis for Sustainability Excellence November 5 2024

Thomas Glanzmann becomes non-executive Chairman September 23 2024

Grifols Accelerates Performance in Q2 and Reaffirms Full Year Guidance July 30 2024

Grifols and Andorran government agree not to proceed with immunology research center July 25 2024

Grifols appoints Rahul Srinivasan as new Chief Financial Officer July 4 2024

Grifols’ Biotest to achieve USD 1 billion in US sales of Yimmugo® over next seven years July 1 2024

Grifols completes sale of a 20% equity stake in SRAAS and forges strategic alliance with Haier Group June 18 2024

Grifols shareholders approve all agenda items at 2024 Annual General Meeting June 14 2024

Grifols succesfully closes the issuance of additional EUR 300 million secured notes June 4 2024

Grifols on track to meet full-year guidance and reduce debt May 14 2024

Grifols on track to close its strategic alliance with Haier in first half 2024 May 6 2024

Grifols successfully completes its EUR 1 billion private placement of senior secured notes April 30 2024

Grifols announces signing of private offering of EUR 1 billion senior secured notes due 2030 April 23 2024

Nacho Abia begins tenure as new Grifols CEO April 2 2024

Grifols shares CNMV statement March 25 2024

Grifols closes a record year and accelerates profitable growth for 2024 February 29 2024

Grifols announces changes in governance to separate management from ownership as part of planned strategy February 5 2024

Grifols’ Credit Rating Affirmed by S&P Global; Outlook Stable January 19 2024

Grifols reaches strategic alliance with Haier Group and raises approximately USD 1.8 billion December 29 2023

Victor Grifols Roura announces retirement from the Board of Directors; Albert Grifols Coma-Cros appointed as new Board Member December 19 2023

Grifols renews its inclusion in the Dow Jones Sustainability Indices as one of the world s most sustainable companies December 11 2023

Grifols accelerates EBITDA margin expansion to 25.1% and further improves its operating performance November 2 2023

Grifols delivers 15% revenue growth, accelerates margin expansion in Q2 and raises guidance for FY23 July 27 2023

Grifols delivers strong first quarter financials with 23% revenue growth and an Adjusted EBITDA margin above guidance of 21% May 9 2023

Grifols realigns management structure to accelerate company performance and simplify its corporate governance May 8 2023

Grifols delivers strong 2022 performance and is positioned for sustainable future growth February 28 2023

Thomas Glanzmann new Grifols Executive Chairman, after Steven F. Mayer resignation February 21 2023

Grifols announces comprehensive operational improvement plan including EUR 400 million annualized cost savings initiative February 15 2023

Grifols included in Bloomberg Gender-Equality Index for the third consecutive year for its leadership in equality, diversity and inclusion January 31 2023

Grifols recognized as one of the world’s most sustainable companies by Dow Jones Sustainability Index for third consecutive year December 12 2022

Grifols’ Biopharma delivers robust 34% operational growth in Q3, driving revenues to EUR 4,351m in the first nine months of 2022 November 8 2022

Grifols invites to listen to webcast of November 8 Conference Call with Analysts November 4 2022

Victor Grifols Roura decides to retire as Chairperson; Grifols appoints private equity veteran Steven F. Mayer as Executive Chairperson October 3 2022

Board of Directors communication in the context of considerable geopolitical uncertainty and market volatility September 26 2022

Grifols’ credit rating reaffirmed by Moody’s and Fitch based on strong fundamentals and improving performance September 23 2022

Grifols enters into agreement with Canadian Blood Services to accelerate self-sufficiency in immunoglobulins for Canada September 7 2022

Grifols’ business momentum delivers EUR 2,810 million in revenues and EUR 618 million in EBITDA as plasma collections accelerate July 28 2022

Grifols highlights the acceleration of its operating performance and reiterates its strong commitment to debt reduction June 16 2022

Grifols highlights an increase in plasma and underscores innovation and sustainability as key growth pillars in its AGM June 10 2022

Business Update 1Q 2022: Grifols accelerating plasma recovery while enhancing performance May 6 2022

Grifols completes the acquisition of Biotest: a strategic and transformational transaction to accelerate growth and innovation April 25 2022

Grifols demonstrates resilient performance despite a challenging backdrop while recovery in plasma collection gains momentum February 28 2022

Grifols signs global collaboration agreement with Endpoint Health to develop and commercialize Antithrombin III for Sepsis February 24 2022

Grifols maintains its standing in the Bloomberg Gender-Equality Index for its commitment to equality January 26 2022

Grifols achieves a high level of acceptance of its PTO to Biotest and advances on its strategic transaction January 26 2022

Grifols announces the expiration of the Asset sale Offer January 11 2022